Here are the top 5 biosimilar articles for the week of October 18, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of October 18, 2021.
Number 5: Hopes that insulin biosimilars can improve access and affordability will be tested by Express Scripts’ plan to give preferred formulary status to Semglee, a long-acting insulin that is interchangeable with Lantus.
Number 4: Switching between reference adalimumab (Humira) and its approved biosimilars results in no differences in efficacy, safety, and immunogenicity, investigators in Spain have concluded following a systematic review of available studies.
Number 3: An additional 1.2 million patients could benefit from biosimilars by 2025, according to a specialty pharmacy report by CoverMyMeds, a division of McKesson. The report discusses payer/pharmacy benefit manager consolidation, patient adherence, white bagging, and other issues common to specialty pharma.
Number 2: In a recent interview, Gary Lyman, MD, MPH, an oncologist and hematologist and public health researcher with the Hutchinson Institute for Cancer Outcomes Research, compares the uptake of biosimilars for cancer care and other conditions and provides insight on how uptake could be improved.
Number 1: The FDA has approved an interchangeable designation for Boehringer Ingelheim’s adalimumab biosimilar Cyltezo, which was originally approved in August 2017 and is scheduled to go on the market on July 1, 2023.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?